SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001193125-23-090937
Filing Date
2023-04-04
Accepted
2023-04-04 16:33:18
Documents
20

Document Format Files

Seq Description Document Type Size
1 PRE 14A d471617dpre14a.htm   iXBRL PRE 14A 814071
6 GRAPHIC g471617dsp007.jpg GRAPHIC 207586
7 GRAPHIC g471617dsp008.jpg GRAPHIC 250801
8 GRAPHIC g471617dsp009.jpg GRAPHIC 246649
9 GRAPHIC g471617g01a51.jpg GRAPHIC 118872
10 GRAPHIC g471617g01a52.jpg GRAPHIC 126841
11 GRAPHIC g471617g02s02.jpg GRAPHIC 33489
  Complete submission text file 0001193125-23-090937.txt   4358856

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20221231.xsd EX-101.SCH 6189
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE qncx-20221231_def.xml EX-101.DEF 6980
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20221231_lab.xml EX-101.LAB 9851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20221231_pre.xml EX-101.PRE 6344
14 EXTRACTED XBRL INSTANCE DOCUMENT d471617dpre14a_htm.xml XML 356821
Mailing Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38890 | Film No.: 23798332
SIC: 2836 Biological Products, (No Diagnostic Substances)